JangoBio claims a scientific breakthrough in developing sustainable stem-cell based organoids for hormone restoration.

Having recently closed a $2m seed round, researchers at JangoBio’s Wisconsin laboratory announced that they have successfully created organoids to emulate the production of ovarian and testicular hormones. They claim their approach has the capacity to regenerate and replace hormone-producing tissues and reverse the natural decline of sex hormones that occurs with age.

“The development of hormone-producing organoids paves the way for use in humans and animals,” said Dr Craig Atwood, CEO. “JangoBio is rapidly moving towards testing of our organoid products in animal models.” [1]

Restoration of circulating hormone concentrations offers the benefits of preventing the symptoms of menopause and male andropause – potentially halting age-related disease and increasing the healthy lifespan of humans and animals.

Restoration of circulating hormone concentrations offers the benefits of preventing the symptoms of menopause and male andropause – potentially halting age-related disease and increasing the healthy lifespan of humans and animals. The JangoBio team think that implanted organoids may well be the first cell-based therapies to fully reverse hormonal decline and the associated age-related diseases, claiming that organoid-based hormone therapies are superior to traditional single hormone-based therapies, allowing restoration of all hormones produced by the ovaries and testes.

Beginning with companion animals, treatments will be administered by veterinary clinics throughout North America. The next phase of development will introduce these therapies into human clinical trials.

JangoBio utilises regenerative stem-cell based precision medicine to restore circulating hormone balance required for optimal health and Longevity.

[1] https://bit.ly/39W2YOB